Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.49 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.49 |
| ▸ | GABRG2 | P18507 | 1/20 | 0.49 |
| ▸ | GABRB3 | P28472 | 1/20 | 0.49 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.49 |
| ▸ | GABRA2 | P47869 | 1/20 | 0.49 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.49 |
| ▸ | AOX1 | Q06278 | 1/20 | 0.49 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.49 |
| ▸ | TLR8 | Q9NR97 | 1/20 | 0.47 |
| ▸ | MAP2K1 | Q02750 | 1/20 | 0.42 |
| ▸ | CLK4 | Q9HAZ1 | 1/20 | 0.42 |
| ▸ | DYRK1B | Q9Y463 | 1/20 | 0.42 |
| ▸ | BRAF | P15056 | 7/20 | 0.41 |
| ▸ | CDKN1A | P38936 | 1/20 | 0.41 |
| ▸ | MAPK13 | O15264 | 2/20 | 0.41 |
| ▸ | LIMK1 | P53667 | 1/20 | 0.41 |
| ▸ | MARK2 | Q7KZI7 | 1/20 | 0.41 |
| ▸ | PIM1 | P11309 | 3/20 | 0.40 |
| ▸ | GSK3A | P49840 | 3/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1879430 | 0.94 | KDM4E (0.49) | KDM4EGABRA1GABRG2GABRB3MAPK1 | |
| SCHEMBL1883448 | 0.93 | KDM4E (0.49) | KDM4EGABRA1GABRG2GABRB3MAPK1 | |
| SCHEMBL1880154 | 0.92 | TLR8 (0.51) | KDM4EGABRA1GABRG2GABRB3MAPK1 | |
| SCHEMBL1876911 | 0.91 | KDM4E (0.48) | KDM4EGABRA1GABRG2GABRB3MAPK1 | |
| SCHEMBL1877724 | 0.90 | TLR8 (0.44) | KDM4EGABRA1GABRG2GABRB3MAPK1 | |
| SCHEMBL1873926 | 0.90 | KDM4E (0.51) | KDM4EGABRA1GABRG2GABRB3MAPK1 | |
| SCHEMBL1879312 | 0.88 | TLR8 (0.49) | KDM4EGABRA1GABRG2GABRB3MAPK1 | |
| SCHEMBL1878696 | 0.87 | CDKN1A (0.57) | KDM4EGABRA1GABRG2GABRB3MAPK1 | |
| SCHEMBL1875584 | 0.87 | KDM4E (0.48) | KDM4EGABRA1GABRG2GABRB3MAPK1 | |
| SCHEMBL1873521 | 0.86 | KDM4E (0.49) | KDM4EGABRA1GABRG2GABRB3MAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7947688-B2 | N-[3-(3-substituted-pyrazolo[1,5-a]pyrimidin-7-yl)phenyl]-sulfonamides, and compositions, and methods related thereto | FERRER INTERNACIONAL, S.A. (ES) | 2011-05-24 | — | — | US | claimed |
| EP-1648897-B1 | N- [3-(3-SUBSTITUTED-PYRAZOLO[1,5-A] PYRIMIDIN-7-YL) PHENYL]-SULFONAMIDES, AND COMPOSITIONS, AND METHODS RELATED THERETO | FERRER INT (ES) | 2008-12-10 | — | — | EP | claimed |
| US-20060270690-A1 | N-[3-(3-substituted-pyrazolo[1,5-a]pyrimidin-7-yl)phenyl]-sulfonamides, and compositions, and methods related thereto | FERRER INTERNACIONAL S.A. (ES) | 2006-11-30 | — | — | US | claimed |
| EP-1648897-A1 | N- [3-(3-SUBSTITUTED-PYRAZOLO[1,5-A] PYRIMIDIN-7-YL) PHENYL]-SULFONAMIDES, AND COMPOSITIONS, AND METHODS RELATED THERETO | FERRER INTERNACIONAL, S.A. (ES) | 2006-04-26 | — | — | EP | claimed |
| WO-2005014597-A1 | N-[3-(3-SUBSTITUTED-PYRAZOLO[1,5-a]PYRIMIDIN-7-YL)PHENYL]-SULFONAMIDES, AND COMPOSITIONS, AND METHODS RELATED THERETO | FERRER INTERNACIONAL, S.A. (ES) | 2005-02-17 | — | — | WO | claimed |
| US-7947688-B2 | N-[3-(3-substituted-pyrazolo[1,5-a]pyrimidin-7-yl)phenyl]-sulfonamides, and compositions, and methods related thereto | FERRER INTERNACIONAL, S.A. (ES) | 2011-05-24 | — | — | US | disclosed |
| EP-1648897-B1 | N- [3-(3-SUBSTITUTED-PYRAZOLO[1,5-A] PYRIMIDIN-7-YL) PHENYL]-SULFONAMIDES, AND COMPOSITIONS, AND METHODS RELATED THERETO | FERRER INT (ES) | 2008-12-10 | — | — | EP | disclosed |
| US-20060270690-A1 | N-[3-(3-substituted-pyrazolo[1,5-a]pyrimidin-7-yl)phenyl]-sulfonamides, and compositions, and methods related thereto | FERRER INTERNACIONAL S.A. (ES) | 2006-11-30 | — | — | US | disclosed |
| EP-1648897-A1 | N- [3-(3-SUBSTITUTED-PYRAZOLO[1,5-A] PYRIMIDIN-7-YL) PHENYL]-SULFONAMIDES, AND COMPOSITIONS, AND METHODS RELATED THERETO | FERRER INTERNACIONAL, S.A. (ES) | 2006-04-26 | — | — | EP | disclosed |
| WO-2005014597-A1 | N-[3-(3-SUBSTITUTED-PYRAZOLO[1,5-a]PYRIMIDIN-7-YL)PHENYL]-SULFONAMIDES, AND COMPOSITIONS, AND METHODS RELATED THERETO | FERRER INTERNACIONAL, S.A. (ES) | 2005-02-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060270690-A1 | N-[3-(3-substituted-pyrazolo[1,5-a]pyrimidin-7-yl)phenyl]-sulfonamides, and compositions, and methods related thereto | GABRA2, GABRA1, GABRA3 | KDM4E 3264/4885GABRA1 2/4885GABRG2 14/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.